GLYCのチャート
GLYCの企業情報
| symbol | GLYC |
|---|---|
| 会社名 | GlycoMimetics Inc （グリコ・ミメティックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 GlycoMimetics Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate GMI-1070 (Rivipansel) for the treatment of vaso-occlusive crisis (VOC) a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271 a specific E-selectin inhibitor to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML) multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate GMI-1359 that targets both E-selectin and a chemokine receptor CXCR4. The Company is also advancing other preclinical-stage programs which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9. グリコ・ミメティックスは希少薬の発見と開発を行う米国のバイオ医薬品会社。鎌状赤血球病患者の血管閉鎖性発作の治療薬GMI-1070、急性骨髄性白血病と血液凝固障害の治療薬GMI-1271の治験を行う。また、緑膿菌毒性因子をタ―ゲットにした治療薬の開発を行う。 GlycoMimetics is a biotechnology company with a focus in hematology-oncology and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including in a Company-sponsored Phase 3 trial in relapsed/refractory AML. GlycoMimetics has an ongoing Phase 1b clinical trial evaluating GMI-1359, a combined CXCR4 and E-selectin antagonist, also a wholly-owned drug candidate. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. |
| 本社所在地 | 9708 Medical Center Drive Rockville MD 20850 USA |
| 代表者氏名 | M. James E. Barrett M.ジェームスE.バレット |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 240-243-1201 |
| 設立年月日 | 37712 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | － |
| url | www.glycomimetics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/glyc |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -41.46510 |
| 終値（lastsale） | 13.62 |
| 時価総額（marketcap） | 586439976.54 |
| 時価総額 | 時価総額（百万ドル） 609.26030 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 379.82560 |
| 当期純利益 | 当期純利益（百万ドル） -39.99956 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 GlycoMimetics Inc revenues was not reported. Net loss increased 42% to $22.8M. Higher net loss reflects researcg and development expense balanc increase of 59% to $17.5M (expense) General_Administrative Expe increase of 26% to $4.3M (expense) Stock-based Compensation in R&D increase of 36% to $853K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.64 to -$0.59. |
GLYCのテクニカル分析
GLYCのニュース
GlycoMimetics Has Few Risks, Great Outlook In Leukemia (NASDAQ:GLYC) 2023/04/04 12:35:08 Seeking Alpha
GlycoMimetics'' lead drug candidate is in Phase 3 development for multiple leukemia indications. See why we recommend a buy on GLYC.
GlycoMimetics, Inc. (GLYC) Q4 2022 Earnings Call Transcript 2023/03/29 15:09:04 Seeking Alpha
GlycoMimetics, Inc. (NASDAQ:NASDAQ:GLYC) Q4 2022 Results Conference Call March 29, 2023 8:30 AM ETCompany ParticipantsChristian Dinneen-Long - General Counsel and Company SecretaryHarout…
GlycoMimetics: Q4 Earnings Snapshot 2023/03/29 11:06:28 WTOP
ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — GlycoMimetics Inc. (GLYC) on Wednesday reported a loss of $10.2 million in…
GlycoMimetics GAAP EPS of -$0.19 misses by $0.02 2023/03/29 11:04:13 Seeking Alpha
GlycoMimetics press release (GLYC): Q4 GAAP EPS of -$0.19 misses by $0.02.Cash and cash equivalents as of December 31, 2022 were $47.9 million.Cash and cash equivalents expected to…
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022 2023/03/29 11:00:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the quarter and year ended December 31, 2022. Cash and cash equivalents as of December 31, 2022 were $47.9 million. After year-end, the company raised an additional $28.7 million in net proceeds from its “at-the-market” (ATM) sales faci
Do you want to know where to find good stock? Take a look at GlycoMimetics Inc.’s (NASDAQ:GLYC) Sentiment Analysis 2023/01/30 20:08:00 US Post News
Currently, GlycoMimetics Inc.’s (GLYC) stock is trading at $3.03, marking a fall of -10.62% from last night’s close. At this price, the stock is -15.83% below its 52-week high of $3.60 and 494.12% above its 52-week low of $0.51. Based on the past 30-day period, the stock price is -15.28% below the high and +26.03% […]
Surprising stocks: Meiwu Technology Company Limited (NASDAQ:WNW 6.67%), GlycoMimetics, Inc. (NASDAQ:GLYC -2.21%) 2023/01/26 13:55:07 Stock Equity
WNW has seen its SMA50 which is now -71.32%. In looking the SMA 200 we see that the stock has seen a -67.17%. GLYC has seen its SMA50 which is … The post Surprising stocks: Meiwu Technology Company Limited (NASDAQ:WNW 6.67%), GlycoMimetics, Inc. (NASDAQ:GLYC -2.21%) appeared first on Stocks Equity .
GlycoMimetics Inc. (GLYC) deserves closer scrutiny 2023/01/11 16:00:00 US Post News
A share of GlycoMimetics Inc. (NASDAQ:GLYC) closed at $2.90 per share on Tuesday, up from $2.78 day before. While GlycoMimetics Inc. has overperformed by 4.32%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, GLYC rose by 108.63%, with highs and lows ranging from $3.30 to $0.51, […]
GlycoMimetics: A Cancer-Cure Lottery Ticket Grabbing My Attention (NASDAQ:GLYC) 2023/01/03 12:40:57 Seeking Alpha
GlycoMimetics may have discovered a successful treatment for AML leukemia, currently with a 5-year survival rate of around 30%. Find out why GLYC is a Buy.
GlycoMimetics Inc. (NASDAQ: GLYC) Stock Forecast: $13.00 Per Share In 2022 With Positive Signs 2022/12/28 21:00:00 Marketing Sentinel
In today’s recent session, 0.85 million shares of the GlycoMimetics Inc. (NASDAQ:GLYC) have been traded, and its beta is 2.32. Most recently the company’s share price was $2.38, and it changed around $0.14 or 6.23% from the last close, which brings the market valuation of the company to $116.93M. GLYC at last check was trading … GlycoMimetics Inc. (NASDAQ: GLYC) Stock Forecast: $13.00 Per Share In 2022 With Positive Signs Read More »
Investing in GlycoMimetics Inc. (GLYC) might be a great opportunity, but the stock is a bit overvalued 2022/11/29 14:00:00 US Post News
As of Monday, GlycoMimetics Inc.’s (NASDAQ:GLYC) stock closed at $2.15, up from $2.05 the previous day. While GlycoMimetics Inc. has overperformed by 4.88%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, GLYC rose by 20.11%, with highs and lows ranging from $2.43 to $0.51, whereas the […]
GlycoMimetics Inc. (NASDAQ:GLYC) Is -1.44% Lower Than A Week Ago, Can It Hit Well Above -$0.03? 2022/11/26 13:00:00 Marketing Sentinel
In last trading session, GlycoMimetics Inc. (NASDAQ:GLYC) saw 0.27 million shares changing hands with its beta currently measuring 1.97. Company’s recent per share price level of $2.05 trading at -$0.04 or -1.91% at ring of the bell on the day assigns it a market valuation of $99.30M. That closing price of GLYC’s stock is at … GlycoMimetics Inc. (NASDAQ:GLYC) Is -1.44% Lower Than A Week Ago, Can It Hit Well Above -$0.03? Read More »
How did GlycoMimetics Inc. (GLYC) fare last session? 2022/11/21 14:40:00 US Post News
GlycoMimetics Inc. (NASDAQ:GLYC) closed Friday at $2.25 per share, up from $2.08 a day earlier. While GlycoMimetics Inc. has overperformed by 8.17%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, GLYC rose by 22.28%, with highs and lows ranging from $2.12 to $0.51, whereas the simple […]
BRY, CRCT and IMRX are among after hour movers 2022/11/16 23:06:24 Seeking Alpha
Gainers: GlycoMimetics (GLYC) +9%. EDAP TMS (EDAP) +6%
Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday 2022/11/14 07:35:17 Benzinga
Gainers ShiftPixy, Inc. (NASDAQ: PIXY ) shares surged 56.6% to settle at $19.10 on Friday. Shares of several companies in the broader industrial space traded higher on continued hopes of softer Fed policy after CPI this week showed October inflation below estimates. Exela Technologies, Inc. (NASDAQ: XELA ) gained 50.3% to close at $0.2780. The company is expected to report Q3 results on November 14, 2022. uCloudlink Group Inc. (NASDAQ: UCL ) jumped 49.6% to close at $1.90. uCloudlink Group is expected to report Q3 financial results on November 16, 2022. Core Scientific, Inc. (NASDAQ: CORZ ) gained 44.3% to settle at $0.1981. Compass, Inc. (NYSE: COMP ) jumped 44% to close at $3.50. Compass posted a wider-than-expected loss for its third quarter, while sales topped estimates. Kaleyra, Inc. (NYSE: KLR ) climbed 38.5% to close at $0.90. Kaleyra extended Oracle partnership to leverage Oracle Cloud. Nutex Health Inc. (NASDAQ: NUTX ) gained 37.7% to close at $1.16. MiNK Therapeutics, Inc. (NASDAQ: INKT ) jumped 35.8% to close at $3.00.